Corcept Therapeutics vs Innoviva
Corcept Therapeutics reported revenue of $761 million in fiscal 2025, 1.9 times Innoviva's $411 million in fiscal 2025. Corcept Therapeutics' revenue grew 12.8% in its latest year, and Innoviva's grew 14.7%. Corcept Therapeutics had an operating margin of 5.9%, against 39.8% at Innoviva. Free cash flow was $142 million at Corcept Therapeutics and $196 million at Innoviva.
Side by side
| Corcept Therapeutics | Innoviva | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $761M | $411M |
| Revenue growth | 12.8% | 14.7% |
| Revenue growth a year, last 5 years | 16.6% | 4.1% |
| Gross margin | 98.3% | 74.8% |
| Operating margin | 5.9% | 39.8% |
| Net margin | 13.1% | 65.9% |
| Free cash flow | $142M | $196M |
| Free cash flow margin | 18.6% | 47.6% |
| Return on capital | 15.7% | 17.9% |
| Net debt to EBITDA | −8.1x | — |
| Dividends and buybacks | $173M | $4M |
| Change in diluted share count | 5.7% | 14.2% |
| Last close | $87.12 | $21.05 |
| P/E at the last close | — | 5.1× |
| Insider trades, last 12 months | bought $3.3 million, sold $96.1 million | — |
| Piotroski F-score | 3 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Corcept TherapeuticsInnoviva
Operating margin
Percent of revenue
Corcept TherapeuticsInnoviva
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Corcept TherapeuticsInnoviva
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Corcept Therapeutics and Innoviva pages.